Jonathan Zalevsky insider trades
Open-market stock purchases and sales by Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, from SEC Form 4 filings since Oct 1, 2019.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 15, 2026 | NKTR Nektar Therapeutics | Sold | $336K |
| May 19, 2026 | NKTR Nektar Therapeutics | Sold | $13K |
| Feb 18, 2026 | NKTR Nektar Therapeutics | Sold | $13.1K |
| Jan 20, 2026 | NKTR Nektar Therapeutics | Sold | $138K |
| Dec 22, 2025 | NKTR Nektar Therapeutics | Bought (not open market) | — |
| Dec 22, 2025 | NKTR Nektar Therapeutics | Bought (not open market) | — |
| Nov 25, 2025 | NKTR Nektar Therapeutics | Sold | $62.8K |
| Nov 21, 2025 | NKTR Nektar Therapeutics | Bought (not open market) | — |
| Nov 21, 2025 | NKTR Nektar Therapeutics | Bought (not open market) | — |
Companies traded
- NKTR Nektar Therapeutics: 37 sales, last Jun 15, 2026